Opinion|Videos|August 26, 2024
Use of PRO in Atopic Dermatitis Clinical Practice
Jonathan Silverberg, MD, PhD, MPH, offers insights on the role of patient-reported outcomes in informing treatment decisions for patients with atopic dermatitis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Patient-reported outcomes (PRO) are important in atopic dermatitis and are increasingly being incorporated in clinical trials.
- Which PRO are you using in your practice?
- Which PRO are you using in your practice?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5